Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Supported by: UKRI EPSRC AI for Health EP/Y017544/1 Disclosure: D
Quick Answer: GLP-1 agonists show preliminary promise for binge eating disorder but lack FDA approval and robust clinical trial evidence for this indication
#83 Olympia Pharmaceuticals Olympia Pharmaceuticals is an accredited 503A/503B compounding operation in Orlando that has been one of the largest sources of compounded injectablesincluding GLP-1sreaching patients through prescribers and telehealth platforms
Your dose may need to go up as your tolerance buildsyour price won't
Two GLP-1s (Saxenda and Wegovy) are currently approved for use in adolescents ages 12 and up
US$ 25.16
US$ 28.97
US$ 26.40
US$ 21.26
